Alnylam Added to NASDAQ Biotechnology Index

23-Nov-2005

Alnylam Pharmaceuticals, Inc. announced that it was added to the NASDAQ biotechnology Index, effective with the U.S. market open on Monday, November 21, 2005.

"We are proud to be selected to join the NASDAQ Biotechnology Index," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "We believe our inclusion in this index reflects the increased awareness in the investment community of the potential of RNAi for therapeutic applications, and the importance of translating this breakthrough in biology into innovative medicines."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances